Neurodegenerative disorders are complex, highly heterogeneous and complicated by co-pathologies. Historically, these challenges have limited progress in the diagnosis and treatment of CNS diseases but the recent emergence of highly sensitive assays to measure blood- based biomarkers is transforming the field.
These advancements are giving renewed hope to researchers with the future possibility of earlier detection, personalized treatment plans and improved patient outcomes across a spectrum of CNS related disorders.
Comprehensive analysis of health and disease
High sensitivity measurement of validated biomarkers
Prof. Jonathan Schott
Alex Forrest-Hay
Carlos Cruchaga, PhDAlex Forrest-Hay
Prof. Charlotte Teunissen
Mathias Holpert
Dr. Gemma Salvadó
Prof. Monique Breteler
Prof. Jonathan Rohrer
Dr. Sanja Kezic
Prof. Amy Fu
Caroline Chan, PhD
Katharina Stracke, PhD
By leveraging multiplexed assays for proteins implicated in neurodegenerative and inflammatory pathways, researchers and clinicians can now gain unprecedented insight into the molecular fingerprints that define distinct neurological disorders. This approach not only supports early diagnosis but also enables nuanced monitoring of disease progression, response to therapies, and patient stratification—paving the way for truly personalized interventions.
Given the heterogeneous pathology of AD and mixed dementia, inflammation, synaptic, and vascular markers can play a key role in understanding disease pathophysiology. By measuring multiple CNS proteins simultaneously, Alamar’s ultra-sensitive NULISA™ multiplex panels can monitor changes across key processes to provide insights beyond the established AT(N) biomarkers. Karikari, et al. demonstrates how multiplexed, blood-based profiling can provide a comprehensive view of AD-associated proteomic changes, consistent with the recently revised biological and diagnostic framework.
Know More↓
PD, PDD and DLB are conditions that all sit on the Lewy body disease spectrum, driven by abnormal aggregation of α-synuclein in the brain, but they differ in timing and clinical presentation. By the time PD or DLB is clinically diagnosed, significant neuronal loss has already occurred and available treatments are only symptomatic and offer diminishing benefits over time. Developing a reliable PD risk score based on molecular biomarkers opens up the potential for disease modifying therapies that could delay or halt disease onset.
Know More↓
Improving ALS outcomes is challenging due to disease complexity and heterogeneity. Plasma-based biomarkers, especially NFL, correlate with axon loss, disease progression, and disease conversion risk in mutation carriers like those with SOD1 variants. Additional biomarkers are needed to identify disease stages, track co-pathologies, and monitor therapy, complementing NFL measurements.
Know More↓
The pathology and outcomes of traumatic brain injury (TBI) are complex and varied, and existing diagnostic methods have limited ability to assess the underlying pathology. Proteomic techniques that use fluid-based biomarkers offer a valuable solution, as they allow for sensitive and thorough evaluation of all processes that may be related to TBI pathophysiology.
Know More↓
MS is a chronic, immune-mediated disorder of the central nervous system characterized by inflammation, demyelination, and neurodegeneration. In recent years, advances in biomarker testing have transformed the landscape of MS research with fluid-based proteomic assays provide a promising avenue for uncovering the complex nature of the disease.
Know More↓
CSO
Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.
CFO
Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.
